Unicycive Therapeutics, Inc.
NASDAQ:UNCYBiotechnology
-$0.24 today
- Market cap
- $104.19M
- Beta
- 1.73
- P/E (TTM)
- -40.8
- EPS (TTM)
- -$0.17
Volume 1.39M
Average 0.65M
UNCY Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Unicycive Therapeutics, Inc.NASDAQ: UNCY
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity rises 234.5% from a year ago
Total equity stood at $37.7M at the end of Q1 FY2026, up 234.5% from a year earlier and up 24.9% from the prior quarter.
Context
- Total equity amounted to 58.5% of total assets at the end of Q1 FY2026, up 18.2 pp from a year earlier.
- Total equity increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +234.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 30.2M USD
- Year-over-year change
- +306.4%
- 4-year CAGR
- +16.3%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 30.2M | +306.4% |
| FY2024 | 2024-12-31 | 7.43M | +295.1% |
| FY2023 | 2023-12-31 | (3.81M) | -717.4% |
| FY2022 | 2022-12-31 | (466K) | -102.8% |
| FY2021 | 2021-12-31 | 16.48M | — |
Total Equity vs competitors
How UNCY compares with its peers on the latest reported figures
- Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +234.5% is the 3rd highest of 10, against a peer median of -40.1%.
- Total equity amounts to 58.5% of total assets for UNCY, versus a peer median of 64.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $218.73M USD | +874.7% | -14.9% | 92.9% | |
| Mar 2026 | $151.23M USD | +2960.5% | — | 79.7% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $95.52M USD | -40.4% | -12.9% | 88.6% |
| Mar 2026 | $94.12M USD | +106.3% | -7.4% | 52.3% | |
| Mar 2026 | $87.97M USD | -45.1% | -24.8% | 91.1% | |
| Mar 2026 | $37.7M USD | +234.5% | — | 58.5% | |
CBUSCibus, Inc. | Mar 2026 | $35.48M USD | -52.0% | +44.5% | 10.9% |
| Mar 2026 | $30.9M USD | -40.1% | — | 29.3% | |
| Mar 2026 | $18.72M USD | -34.9% | -35.2% | 40.4% | |
HYFTMindWalk Holdings Corp. | Jan 2026 | CA$14.98M CAD | -40.4% | -32.0% | 64.6% |
| Peer median (excluding UNCY) | — | -40.1% | -14.9% | 64.6% | |
Competitors are the stored peer set for UNCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
Intrinsic Alpha fair value
Locked
Current Price
$3.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.